Showing results (11-20 of 91) with videos related to
Sort By:
Pageof 10
Future Oncology (London, England)|October 31, 2019
Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant centerHendrik Eggers, Faikah Güler, Ulrike Ehlers, et al.Experimental Hematology|June 21, 2005
Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemiaWenji Piao, Jens Grosse, Andreas Czwalinna, et al.Medical Oncology (Northwood, London, England)|December 31, 2016
c-Met in chromophobe renal cell carcinomaFranziska Erlmeier, Philipp Ivanyi, Arndt Hartmann, et al.Acta Radiologica Open|March 22, 2017
CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational studySabine Dettmer, Viktor Grünwald, Thomas Fuehner, et al.Medical Oncology (Northwood, London, England)|October 4, 2016
PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?Franziska Erlmeier, Arndt Hartmann, Michael Autenrieth, et al.Journal of Cancer Research and Clinical Oncology|August 21, 2020
Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N)Philipp Ivanyi, Carsten Grüllich, Nils Kroeger, et al.Aktuelle Urologie|November 14, 2023
Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancerMelanie Klee, Marie Christine Roesch, Hendrik Eggers, et al.BMC Cancer|January 4, 2011
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinibViktor Gruenwald, Gernot Beutel, Susanne Schuch-Jantsch, et al.World Journal of Urology|May 6, 2010
Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patientsPhilipp Ivanyi, Thomas Winkler, Anika Grosshennig, et al.Medical Oncology (Northwood, London, England)|April 23, 2017
Prognostic impact of PD-1 and its ligands in renal cell carcinomaFranziska Erlmeier, Wilko Weichert, Andres Jan Schrader, et al.Pageof 10